Tomxx
2021-12-16
Like
In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners<blockquote>在生物科技股糟糕的一年里，交易和疫苗成为赢家</blockquote>
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
1
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":690317144,"tweetId":"690317144","gmtCreate":1639634121315,"gmtModify":1639634492484,"author":{"id":3586059298879232,"idStr":"3586059298879232","authorId":3586059298879232,"authorIdStr":"3586059298879232","name":"Tomxx","avatar":"https://static.tigerbbs.com/abd49c57222b3b842f3f9af84b9d5b97","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":14,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Like</p></body></html>","htmlText":"<html><head></head><body><p>Like</p></body></html>","text":"Like","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/690317144","repostId":1151734731,"repostType":4,"repost":{"id":"1151734731","kind":"news","pubTimestamp":1639632498,"share":"https://www.laohu8.com/m/news/1151734731?lang=zh_CN&edition=full","pubTime":"2021-12-16 13:28","market":"us","language":"en","title":"In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners<blockquote>在生物科技股糟糕的一年里，交易和疫苗成为赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1151734731","media":"WSJ","summary":"Biotech stocks have crumbled this year and a number of prominent hedge funds have suffered deep loss","content":"<p>Biotech stocks have crumbled this year and a number of prominent hedge funds have suffered deep losses.</p><p><blockquote>生物科技股今年暴跌，许多著名的对冲基金也遭受了严重损失。</blockquote></p><p> But some biotech investors are thriving by focusing on mergers, short selling and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022.</p><p><blockquote>但一些生物技术投资者通过关注合并、卖空和Covid-19股票而蓬勃发展。一些分析师和投资者表示，这三种策略将在2022年再次证明对生物技术投资者是成功的。</blockquote></p><p> Hedge funds including Perceptive Advisors, OrbiMed Partners, Logos Capital and Cormorant Asset Management run funds that have suffered double-digit percentage losses this year. The SPDR S&P Biotech ETF, an equal-weighted index of biotech stocks, has fallen nearly 23% so far this year, an indication of how widespread the losses have been.</p><p><blockquote>Perceptive Advisors、OrbiMed Partners、Logos Capital和Cormorant Asset Management等对冲基金运营的基金今年遭受了两位数的百分比损失。SPDR S&P Biotech ETF是生物科技股的等权重指数，今年迄今已下跌近23%，这表明损失有多广泛。</blockquote></p><p> But biotech investors have benefited from some big takeovers in the sector. One popular hedge-fund investment: GW Pharmaceuticals PLC, a British company that develops cannabinoid-based prescription medicines,was acquired by Jazz Pharmaceuticals in May for over $7 billion. Dicerna Pharmaceuticals was another takeover play that worked for investors during the year.</p><p><blockquote>但生物技术投资者从该行业的一些大型收购中受益。一项受欢迎的对冲基金投资：GW Pharmaceuticals PLC是一家开发大麻素处方药的英国公司，于5月份被Jazz Pharmaceuticals以超过70亿美元的价格收购。Dicerna Pharmaceuticals是今年另一项对投资者有效的收购策略。</blockquote></p><p> GW Pharma rose about 90% during 2021, before it was acquired, while Dicerna, which recently announced plans to be acquired, is up about 72%. And this week,Pfizer Inc.announced it would buyArena PharmaceuticalsInc., news that almost doubled Arena shares.</p><p><blockquote>GW Pharma在被收购之前的2021年上涨了约90%，而最近宣布计划被收购的Dicerna则上涨了约72%。本周，辉瑞公司宣布将收购Arena PharmaceuticalsInc.，这一消息使Arena的股价几乎翻了一番。</blockquote></p><p> There may be more of these kinds of deals in 2022, investors say, as cash-heavy pharmaceutical companies look to buy growing biotech companies. Smaller biotech companies may be more inclined to sell after suffering in 2021, the investors say.</p><p><blockquote>投资者表示，随着现金充裕的制药公司寻求收购成长中的生物技术公司，2022年可能会有更多此类交易。投资者表示，规模较小的生物技术公司在经历了2021年的困境后可能更倾向于出售。</blockquote></p><p> Biotech short sellers profited in 2021, as well. Cancer company Rafael HoldingsInc.,which gained interest among individual investors due to early signs it might develop a drug to combat pancreatic cancer, tumbled after reporting disappointing Phase 3 data for its drug and experiencing some executive departures. Rafael is down about 77% so far in 2021.</p><p><blockquote>生物技术卖空者也在2021年获利。癌症公司Rafael HoldingsInc.因可能开发一种对抗胰腺癌的药物的早期迹象而引起了个人投资者的兴趣，在报告其药物令人失望的3期数据并经历了一些高管离职后，该公司股价暴跌。2021年迄今为止，拉斐尔股价下跌了约77%。</blockquote></p><p> Some traders lost money because they hedged their biotech portfolios with bets against the S&P 500, which is up over 20% on the year.</p><p><blockquote>一些交易员亏损是因为他们通过做空标普500来对冲其生物技术投资组合，该指数今年上涨了20%以上。</blockquote></p><p> Of course, Covid-19 vaccine stocks were the stars of 2021, though many have fallen sharply from recent highs. Moderna started the year over $100, approached $500 in the summer, and now trades around $275, still up sharply on the year.</p><p><blockquote>当然，新冠肺炎疫苗股是2021年的明星，尽管许多疫苗股已从近期高点大幅下跌。Moderna年初超过100美元，夏季接近500美元，现在交易价格约为275美元，仍较去年大幅上涨。</blockquote></p><p> “Anything that’s Covid-related has done well, or at least held up,” says Brad Loncar at Loncar Investments, which created two biotech exchange-traded funds.</p><p><blockquote>Loncar Investments的布拉德·隆卡(Brad Loncar)表示：“任何与新冠病毒相关的投资都表现良好，或者至少保持住了。”该公司创建了两只生物技术交易所交易基金。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/11261b7a0f9858c916f503bddf94a00b\" tg-width=\"833\" tg-height=\"735\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> A new urgency for booster shots, as well as a potential need for reworked vaccines to protect against Omicron, could boost sales for Moderna,Pfizer and other Covid-19 vaccine companies.</p><p><blockquote>加强注射的新紧迫性，以及对返工疫苗以预防奥密克戎病毒的潜在需求，可能会促进Moderna、辉瑞和其他Covid-19疫苗公司的销售。</blockquote></p><p> “There will be a strong and continued push for people to get boosted,” says Michael Yee of Jefferies. He adds that there will be strong consideration from health authorities and others for new versions of an Omicron-specific vaccine.</p><p><blockquote>杰富瑞(Jefferies)的迈克尔·易(Michael Yee)表示：“人们将会得到强劲且持续的推动。”他补充说，卫生当局和其他机构将大力考虑新版本的奥密克戎专用疫苗。</blockquote></p><p> Mr. Yee notes that both Moderna and Pfizer have plans to update their vaccines, if needed. But he has long had a “hold” rating on Moderna, due to what he describes as the stock’s already high valuation, a sign that strong prospects for these companies may not lead to strong gains.</p><p><blockquote>Yee先生指出，如果需要，Moderna和辉瑞都计划更新他们的疫苗。但他长期以来一直对Moderna给予“持有”评级，因为他称该股估值已经很高，这表明这些公司的强劲前景可能不会带来强劲上涨。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>In a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners<blockquote>在生物科技股糟糕的一年里，交易和疫苗成为赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIn a Bad Year for Biotech Stocks, Deals and Vaccines Were Winners<blockquote>在生物科技股糟糕的一年里，交易和疫苗成为赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-12-16 13:28</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Biotech stocks have crumbled this year and a number of prominent hedge funds have suffered deep losses.</p><p><blockquote>生物科技股今年暴跌，许多著名的对冲基金也遭受了严重损失。</blockquote></p><p> But some biotech investors are thriving by focusing on mergers, short selling and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022.</p><p><blockquote>但一些生物技术投资者通过关注合并、卖空和Covid-19股票而蓬勃发展。一些分析师和投资者表示，这三种策略将在2022年再次证明对生物技术投资者是成功的。</blockquote></p><p> Hedge funds including Perceptive Advisors, OrbiMed Partners, Logos Capital and Cormorant Asset Management run funds that have suffered double-digit percentage losses this year. The SPDR S&P Biotech ETF, an equal-weighted index of biotech stocks, has fallen nearly 23% so far this year, an indication of how widespread the losses have been.</p><p><blockquote>Perceptive Advisors、OrbiMed Partners、Logos Capital和Cormorant Asset Management等对冲基金运营的基金今年遭受了两位数的百分比损失。SPDR S&P Biotech ETF是生物科技股的等权重指数，今年迄今已下跌近23%，这表明损失有多广泛。</blockquote></p><p> But biotech investors have benefited from some big takeovers in the sector. One popular hedge-fund investment: GW Pharmaceuticals PLC, a British company that develops cannabinoid-based prescription medicines,was acquired by Jazz Pharmaceuticals in May for over $7 billion. Dicerna Pharmaceuticals was another takeover play that worked for investors during the year.</p><p><blockquote>但生物技术投资者从该行业的一些大型收购中受益。一项受欢迎的对冲基金投资：GW Pharmaceuticals PLC是一家开发大麻素处方药的英国公司，于5月份被Jazz Pharmaceuticals以超过70亿美元的价格收购。Dicerna Pharmaceuticals是今年另一项对投资者有效的收购策略。</blockquote></p><p> GW Pharma rose about 90% during 2021, before it was acquired, while Dicerna, which recently announced plans to be acquired, is up about 72%. And this week,Pfizer Inc.announced it would buyArena PharmaceuticalsInc., news that almost doubled Arena shares.</p><p><blockquote>GW Pharma在被收购之前的2021年上涨了约90%，而最近宣布计划被收购的Dicerna则上涨了约72%。本周，辉瑞公司宣布将收购Arena PharmaceuticalsInc.，这一消息使Arena的股价几乎翻了一番。</blockquote></p><p> There may be more of these kinds of deals in 2022, investors say, as cash-heavy pharmaceutical companies look to buy growing biotech companies. Smaller biotech companies may be more inclined to sell after suffering in 2021, the investors say.</p><p><blockquote>投资者表示，随着现金充裕的制药公司寻求收购成长中的生物技术公司，2022年可能会有更多此类交易。投资者表示，规模较小的生物技术公司在经历了2021年的困境后可能更倾向于出售。</blockquote></p><p> Biotech short sellers profited in 2021, as well. Cancer company Rafael HoldingsInc.,which gained interest among individual investors due to early signs it might develop a drug to combat pancreatic cancer, tumbled after reporting disappointing Phase 3 data for its drug and experiencing some executive departures. Rafael is down about 77% so far in 2021.</p><p><blockquote>生物技术卖空者也在2021年获利。癌症公司Rafael HoldingsInc.因可能开发一种对抗胰腺癌的药物的早期迹象而引起了个人投资者的兴趣，在报告其药物令人失望的3期数据并经历了一些高管离职后，该公司股价暴跌。2021年迄今为止，拉斐尔股价下跌了约77%。</blockquote></p><p> Some traders lost money because they hedged their biotech portfolios with bets against the S&P 500, which is up over 20% on the year.</p><p><blockquote>一些交易员亏损是因为他们通过做空标普500来对冲其生物技术投资组合，该指数今年上涨了20%以上。</blockquote></p><p> Of course, Covid-19 vaccine stocks were the stars of 2021, though many have fallen sharply from recent highs. Moderna started the year over $100, approached $500 in the summer, and now trades around $275, still up sharply on the year.</p><p><blockquote>当然，新冠肺炎疫苗股是2021年的明星，尽管许多疫苗股已从近期高点大幅下跌。Moderna年初超过100美元，夏季接近500美元，现在交易价格约为275美元，仍较去年大幅上涨。</blockquote></p><p> “Anything that’s Covid-related has done well, or at least held up,” says Brad Loncar at Loncar Investments, which created two biotech exchange-traded funds.</p><p><blockquote>Loncar Investments的布拉德·隆卡(Brad Loncar)表示：“任何与新冠病毒相关的投资都表现良好，或者至少保持住了。”该公司创建了两只生物技术交易所交易基金。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/11261b7a0f9858c916f503bddf94a00b\" tg-width=\"833\" tg-height=\"735\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> A new urgency for booster shots, as well as a potential need for reworked vaccines to protect against Omicron, could boost sales for Moderna,Pfizer and other Covid-19 vaccine companies.</p><p><blockquote>加强注射的新紧迫性，以及对返工疫苗以预防奥密克戎病毒的潜在需求，可能会促进Moderna、辉瑞和其他Covid-19疫苗公司的销售。</blockquote></p><p> “There will be a strong and continued push for people to get boosted,” says Michael Yee of Jefferies. He adds that there will be strong consideration from health authorities and others for new versions of an Omicron-specific vaccine.</p><p><blockquote>杰富瑞(Jefferies)的迈克尔·易(Michael Yee)表示：“人们将会得到强劲且持续的推动。”他补充说，卫生当局和其他机构将大力考虑新版本的奥密克戎专用疫苗。</blockquote></p><p> Mr. Yee notes that both Moderna and Pfizer have plans to update their vaccines, if needed. But he has long had a “hold” rating on Moderna, due to what he describes as the stock’s already high valuation, a sign that strong prospects for these companies may not lead to strong gains.</p><p><blockquote>Yee先生指出，如果需要，Moderna和辉瑞都计划更新他们的疫苗。但他长期以来一直对Moderna给予“持有”评级，因为他称该股估值已经很高，这表明这些公司的强劲前景可能不会带来强劲上涨。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/in-a-bad-year-for-biotech-stocks-deals-and-vaccines-were-winners-11639564381?mod=markets_lead_pos5\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DRNA":"Dicerna Pharmaceuticals, Inc.","PFE":"辉瑞","MRNA":"Moderna, Inc.","JAZZ":"爵士制药"},"source_url":"https://www.wsj.com/articles/in-a-bad-year-for-biotech-stocks-deals-and-vaccines-were-winners-11639564381?mod=markets_lead_pos5","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1151734731","content_text":"Biotech stocks have crumbled this year and a number of prominent hedge funds have suffered deep losses.\nBut some biotech investors are thriving by focusing on mergers, short selling and Covid-19 stocks. Some analysts and investors say these three strategies will prove successful for biotech investors once again in 2022.\nHedge funds including Perceptive Advisors, OrbiMed Partners, Logos Capital and Cormorant Asset Management run funds that have suffered double-digit percentage losses this year. The SPDR S&P Biotech ETF, an equal-weighted index of biotech stocks, has fallen nearly 23% so far this year, an indication of how widespread the losses have been.\nBut biotech investors have benefited from some big takeovers in the sector. One popular hedge-fund investment: GW Pharmaceuticals PLC, a British company that develops cannabinoid-based prescription medicines,was acquired by Jazz Pharmaceuticals in May for over $7 billion. Dicerna Pharmaceuticals was another takeover play that worked for investors during the year.\nGW Pharma rose about 90% during 2021, before it was acquired, while Dicerna, which recently announced plans to be acquired, is up about 72%. And this week,Pfizer Inc.announced it would buyArena PharmaceuticalsInc., news that almost doubled Arena shares.\nThere may be more of these kinds of deals in 2022, investors say, as cash-heavy pharmaceutical companies look to buy growing biotech companies. Smaller biotech companies may be more inclined to sell after suffering in 2021, the investors say.\nBiotech short sellers profited in 2021, as well. Cancer company Rafael HoldingsInc.,which gained interest among individual investors due to early signs it might develop a drug to combat pancreatic cancer, tumbled after reporting disappointing Phase 3 data for its drug and experiencing some executive departures. Rafael is down about 77% so far in 2021.\nSome traders lost money because they hedged their biotech portfolios with bets against the S&P 500, which is up over 20% on the year.\nOf course, Covid-19 vaccine stocks were the stars of 2021, though many have fallen sharply from recent highs. Moderna started the year over $100, approached $500 in the summer, and now trades around $275, still up sharply on the year.\n“Anything that’s Covid-related has done well, or at least held up,” says Brad Loncar at Loncar Investments, which created two biotech exchange-traded funds.\n\nA new urgency for booster shots, as well as a potential need for reworked vaccines to protect against Omicron, could boost sales for Moderna,Pfizer and other Covid-19 vaccine companies.\n“There will be a strong and continued push for people to get boosted,” says Michael Yee of Jefferies. He adds that there will be strong consideration from health authorities and others for new versions of an Omicron-specific vaccine.\nMr. Yee notes that both Moderna and Pfizer have plans to update their vaccines, if needed. But he has long had a “hold” rating on Moderna, due to what he describes as the stock’s already high valuation, a sign that strong prospects for these companies may not lead to strong gains.","news_type":1,"symbols_score_info":{"DRNA":0.9,"MRNA":0.9,"JAZZ":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2566,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":4,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/690317144"}
精彩评论